Siemens Healthineers is investing $300m in Walpole, Massachusetts laboratory diagnostics manufacturing facility over the next four years.

The investment will expand the facility's capacity, helping to provide better services for the healthcare providers across the globe.

Siemens will use the investment to upgrade and expand its existing 500,000ft² facility. The firm will start renovations at the existing facility in the coming weeks.

It will also build additional manufacturing, warehouse, office and lab space, which is slated to begin in the summer.

With around 700 employees, the Walpole facility produces assays that run on the Advia Centaur family of immunoassay instruments. It also manufactures consumables for the firm’s molecular and blood gas testing instruments.

The facility will also be used to produce assays to run on the immunoassay module of the Atellica solution, which is currently under FDA review.

The new investment is expected to create around 700 new permanent jobs, bringing the total employment at the facility to between 1,300 and 1,600 by 2026.

Siemens Healthineers CEO Bernd Montag said: “The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint in the United States, the largest healthcare market in the world.

“The laboratory instruments and reagents developed and manufactured at the Siemens Healthineers Walpole facility impact patients and healthcare providers across the globe.”

Siemens Healthineers provides products and services, which can be used in the applications such as diagnostic and therapeutic imaging, as well as laboratory diagnostics and molecular medicine.